DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zovirax Topical (Acyclovir Sodium Topical) - Summary

 
 



SUMMARY

ZOVIRAX is the brand name for acyclovir, a synthetic nucleoside analogue active against herpesviruses. ZOVIRAX Cream 5% is a formulation for topical administration.

ZOVIRAX Cream is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and adolescents (12 years of age and older).


See all Zovirax Topical indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Zovirax Topical (Acyclovir Topical)

Picture of Herpes Simplex Virus Type 1
Source: MedicineNet Herpes Simplex Infections (Non-Genital) Specialty [2014.12.09]
Title: Picture of Herpes Simplex Virus Type 1
Category: Images
Created: 10/13/2010 12:51:00 PM
Last Editorial Review: 12/9/2014 12:00:00 AM

Picture of Herpes Simplex Virus Type 2
Source: MedicineNet Sexually Transmitted Diseases (STDs In Women) Specialty [2014.12.09]
Title: Picture of Herpes Simplex Virus Type 2
Category: Images
Created: 10/13/2010 1:10:00 PM
Last Editorial Review: 12/9/2014 12:00:00 AM

Cold Sores (Nongenital Herpes Simplex Infections)
Source: MedicineNet Ganglion Specialty [2013.12.09]
Title: Cold Sores (Nongenital Herpes Simplex Infections)
Category: Diseases and Conditions
Created: 6/16/1999 12:00:00 AM
Last Editorial Review: 12/9/2013 12:00:00 AM

RX approach discovered that reduces herpes virus infection
Source: Sexual Health / STDs News From Medical News Today [2014.12.08]
A multi-institutional study reports an effective treatment approach to inhibit and keep latent viruses like herpes simplex from reactivating and causing disease.

more news >>

Published Studies Related to Zovirax Topical (Acyclovir Topical)

Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. [2009.03]
BACKGROUND: Treatment of herpes simplex labialis (HSL) has been associated with modest benefits. This difficulty results from the rapid resolution of the disease accomplished by the immune system, which narrows the window of therapeutic opportunity. The immune response is also responsible for important clinical manifestations, including oedema and pain. The dual role of immune responses (protection, pathology) is well recognized in other infectious diseases. The addition of corticosteroids to antimicrobial agents has been associated with improvement in some of these diseases. OBJECTIVE: We evaluated the combination of oral valacyclovir plus topical clobetasol compared to placebo for recurrent HSL... CONCLUSIONS: This pilot study supports the addition of topical corticosteroids to an oral antiviral agent for the treatment of HSL. Larger studies need to confirm the safety and efficacy of this approach.

Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: results of a randomized, open-label trial. [2008]
OBJECTIVE: To compare silica gel with acyclovir cream in the treatment of recurrent herpes labialis... CONCLUSIONS: Silica gel was as effective in the treatment of recurrent herpes labialis as acyclovir and equally well tolerated and tended to take effect more quickly. Therefore, silica gel could prove a useful alternative to topical acyclovir.

A random clinical trial study to assess the efficiency of topical applications of podophyllin resin (25%) versus podophyllin resin (25%) together with acyclovir cream (5%) in the treatment of oral hairy leukoplakia. [2007.01]
OBJECTIVE: The objective of this study was to assess the efficiency of topical applications of podophyllin resin (25%) (P) versus podophyllin resin (25%) together with acyclovir cream (5%) (PA) in the treatment of oral hairy leukoplakia (OHL) in accordance with the following criteria: (1) number of applications necessary for the total clinical resolution of OHL; (2) correlation between the decrease of lesion size and the number of applications; (3) total clinical resolution of OHL; and (4) clinical reevaluation 12 months after the end of treatment... CONCLUSIONS: The present study demonstrated the following: (1) P and PA topical treatments presented a similar average number of applications performed weekly; (2) both groups showed the same clinical response at 12 months post-therapy; and (3) PA presented a 100% clinical resolution and a continuous decrease in OHL size over the course of weekly applications.

Topical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo-controlled, clinic-initiated trial. [2006.08.15]
BACKGROUND: Multiple studies of the use of acyclovir for the treatment of herpes labialis have suggested that the nominal efficacy of the topical formulation is the result of inadequate penetration of the drug into the target site of infection, the basal epidermis... CONCLUSIONS: Single-dose topical iontophoresis of acyclovir appears to be a convenient and effective treatment for cold sores and merits further clinical investigation.

Role of acyclovir gel in herpes simplex: clinical implications. [2003.07]
CONCLUSIONS: The results demonstrate that a five-fold reduction in the ACY content in liposomal gel is sufficient for the complete healing of herpetic lesions in HSV-1 and HSV-2 infection. The increased duration of topical therapy may be acceptable for patients suffering from mild herpetic lesions because of the advantage of avoiding systemic and local side effects

more studies >>

Clinical Trials Related to Zovirax Topical (Acyclovir Topical)

A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo) [Recruiting]
Acyclovir is a drug used to treat herpes simplex virus (HSV) infections in babies. Appropriate dosing of acyclovir is known for adults and children but acyclovir has not been adequately studied in full-term or premature neonates. HSV is a very serious infection in babies <6 months of age and often results in death or profound mental retardation. HSV leads to profound mental retardation in young infants because the virus attacks the central nervous system.

The investigators hypothesize that the currently recommended dose of acyclovir is inadequate to produce adequate blood levels to combat herpes simplex infection. The investigators propose to study acyclovir levels in the blood of babies who are placed on acyclovir to treat a suspected HSV infection. This will allow them to determine the appropriate dose in premature infants. This is an unmet public health need because it is likely that the drug behaves differently in premature infants than it does in term infants and older children. Premature babies have more body water and less body tissue. Their kidneys are more immature and do not function as well as full term infants. Premature neonates are also at the greatest risk from herpes infection because they have poorly functioning immature immune systems. Early and appropriate treatment with acyclovir has resulted in improved outcome in term infants.

Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS) [Completed]
To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303 gel in combination with acyclovir, relative to acyclovir alone, for the treatment of recurrent Herpes Simplex Virus (HSV) 1 and 2 infections, affecting the genital, perianal and neighboring areas, in patients with AIDS.

Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2) [Recruiting]
The purpose of this study is to determine whether acyclovir is effective in suppressing HIV viral load in women infected with both HIV-1 and herpes simplex virus type 2 (HSV-2) who are starting HIV treatment for the first time.

Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC) [Recruiting]

The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection [Completed]
This double-blind, placebo-controlled study is designed to determine the long-term safety and efficacy of concurrent oral Retrovir / Zovirax (AZT and ACV) therapy and oral AZT therapy alone, in the treatment of early symptomatic HIV infection. Efficacy will be evaluated by monitoring the incidence, severity, and time of development of opportunistic infections and other manifestations of advanced symptomatic HIV infection. The effects of the combination and single AZT therapy on immune function and viral replication will also be evaluated. Study participants will be monitored for evidence of toxicity or intolerance to concurrent AZT / ACV administration and AZT therapy alone.

more trials >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Zovirax Topical has an overall score of 7. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Zovirax Topical review by 25 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   Shingles
Dosage & duration:   5% cream (dosage frequency: applied as a cream 3 times a day) for the period of 1 week
Other conditions:   None
Other drugs taken:   Calomine Lotion + Pireteze anti histamine tablets
  
Reported Results
Benefits:   taken at a stage where puss filled blisters were swollen, ensured a quick and painless transition from this stage to a stage where blisters became dry. Not much effect for 5 days or so, however when the blisters did dry up they did so quickly and was not painful at all which is what i had expected. fairly easy to apply and good consistency for application.
Side effects:   None
Comments:   applied directly onto affected area 3 times a day. chose to apply generously and cover effected area with a bandage.

See all Zovirax Topical reviews / ratings >>

Page last updated: 2014-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014